Crimson Publishers Publish With Us Reprints e-Books Video articles


Gastroenterology Medicine & Research

Insulin Therapy and Cardiovascular Outcome Trials (Cvots): Any Harm, Anytime?

  • Open or Close Uche Anyanwagu1* and Ifeoma Ezegbulam2

    1University of Nottingham, Royal Derby Hospital, UK

    2Adonai Hospitals, Nigeria

    *Corresponding author: Uche Anyanwagu, Division of Graduate Entry Medicine, School of Medicine, Derby, University of Nottingham, Royal Derby Hospital, UK

Submission: February 25, 2018; Published: March 21, 2018

DOI: 10.31031/GMR.2018.01.000513

ISSN 2637-7632
Volume1 Issue3


The therapeutic management of diabetes may on its own increase the risk of cardiovascular (CV) risk markers – directly or indirectly – through their pharmacological actions (e.g. side effects as hypoglycaemia), or some metabolic changes (e.g. weight-gain, increased BP, etc.). As these risks may not have been anticipated or immediately noticed during clinical trials, 1 post hoc analyses and epidemiological follow up of clinical trials have raised concerns about the CV safety of some drugs used in the management of diabetes.

Get access to the full text of this article

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137